Generic Portal

In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection

Sobesky, S., Mammadova, L., Cirillo, M., Drees, E. E. E., Mattlener, J., Dörr, H., Altmüller, J., Shi, Z., Bröckelmann, P. J., Weiss, J., Kreissl, S., Sasse, S., Ullrich, R. T., Reinke, S., Klapper, W., Gerhard-Hartmann, E., Rosenwald, A., Roemer, M. G. M., Nürnberg, P., Hagenbeek, A., & 6 othersZijlstra, J. M., Pegtel, D. M., Engert, A., Borchmann, P., von Tresckow, B. & Borchmann, S., 8 Oct 2021, In: Med (New York, N.Y.). 2, 10, p. 1171-1193.e11

Research output: Contribution to journal › Article › Academic › peer-review

Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study

Kersten, M. J., Driessen, J., Zijlstra, J. M., Plattel, W. J., Morschhauser, F., Lugtenburg, P. J., Brice, P., Hutchings, M., Gastinne, T., Liu, R., Burggraaff, C. N., Nijland, M., Tonino, S. H., Arens, A. I. J., Valkema, R., van Tinteren, H., Lopez-Yurda, M., Diepstra, A., De Jong, D. & Hagenbeek, A., 1 Apr 2021, In: Haematologica. 106, 4, p. 1129-1137 9 p.

Research output: Contribution to journal › Article › Academic › peer-review

Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials

FLASH group, 23 Mar 2021, In: Blood advances. 5, 6, p. 1737-1745 9 p.

Research output: Contribution to journal › Article › Academic › peer-review

Fair pricing of innovative medicines: An EHA position paper

Hagenbeek, A., Gribben, J., Jäger, U., Kapitein, P., Merlini, G., Piggin, M., Uyl-de Groot, C. A. & Doeswijk, R., 2020, In: HemaSphere. 4, 5, A125.

Research output: Contribution to journal › Article › Academic › peer-review

Here to Stay: Biosimilars in Hematology

Gribben, J., Merlini, G. & Hagenbeek, A., 1 Dec 2019, In: HemaSphere. 3, 6, e323.

Research output: Contribution to journal › Editorial › Academic › peer-review

Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study

Hagenbeek, A., Mooij, H., Zijlstra, J., Lugtenburg, P., van Imhoff, G., Nijland, M., Tonino, S., Hutchings, M., Spiering, M., Liu, R., van Tinteren, H. & Kersten, M. J., Apr 2019, In: Haematologica. 104, 4, p. e151-e153

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

Morschhauser, F., Flinn, I. W., Advani, R., Sehn, L. H., Diefenbach, C., Kolibaba, K., Press, O. W., Salles, G., Tilly, H., Chen, A. I., Assouline, S., Cheson, B. D., Dreyling, M., Hagenbeek, A., Zinzani, P. L., Jones, S., Cheng, J., Lu, D., Penuel, E., Hirata, J., & 3 othersWenger, M., Chu, Y-W. & Sharman, J., 2019, In: Lancet. Haematology. 6, 5, p. e254-e265

Research output: Contribution to journal › Article › Academic › peer-review

Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: A study by the Lunenburg Lymphoma Biomarker Consortium

Rosenwald, A., Bens, S., Advani, R., Barrans, S., Copie-Bergman, C., Elsensohn, M-H., Natkunam, Y., Calaminici, M., Sander, B., Baia, M., Smith, A., Painter, D., Pham, L., Zhao, S., Ziepert, M., Jordanova, E. S., Molina, T. J., Kersten, M. J., Kimby, E., Klapper, W., & 16 othersRaemaekers, J., Schmitz, N., Jardin, F., Stevens, W. B. C., Hoster, E., Hagenbeek, A., Gribben, J. G., Siebert, R., Gascoyne, R. D., Scott, D. W., Gaulard, P., Salles, G., Burton, C., de Jong, D., Sehn, L. H. & Maucort-Boulch, D., 2019, In: Journal of clinical oncology. 37, 35, p. 3359-3368

Research output: Contribution to journal › Article › Academic › peer-review